You are here
Disease modifying therapies
- Journal of Neuroimmunology, Volume 288, 15 November 2015, Pages 92-97
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosisExperimental and Molecular Pathology, Volume 99, Issue 3, December 2015, Pages 498-505
Mojtaba Farjam, Guang-Xian Zhang, Bogoljub Ciric, Abdolmohamad Rostami
Journal of the Neurological Sciences
Teriflunomide: A Once-Daily Oral Medication for the Treatment of Relapsing Forms of Multiple SclerosisClinical Therapeutics, Volume 37, Issue 10, 1 October 2015, Pages 2366–2380
Reduced expression of membrane-bound (m)RAGE is a biomarker of multiple sclerosis disease progressionImmunobiology, Volume 221, Issue 2, February 2016, Pages 193–198
Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients
Katja Pavsic, Katarina Pelicon, Alenka Horvat Ledinek, Sasa Sega
Clinical Neurology and Neurosurgery, Volume 139, December 2015, Pages 35 - 40
Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis
Frédéric Sedel, Delphine Bernard, Donald M. Mock, Ayman Tourbah
Neuropharmacology, Volume 110, Part B, November 2016, Pages 644-653
- Professor Comi emphasized how little was known about the pathophysiology of the progressive phases in relapsing remitting multiple sclerosis. It...
- According to Professor Comi, there had been enormous advances in multiple sclerosis treatment since 1993, when interferon beta-1b was standard...
- Clinicians are mainly concerned with getting patients on treatment, but what do we think about getting patients to stop treatment?...